Industry Overview

US diabetes care drugs market was valued at $34.5 billion in 2025 and is projected to reach $69.6 billion by 2035, growing at a CAGR of 7.4% during the forecast period (2026–2035). The US diabetes care drugs market is experiencing sustained growth due to the rising prevalence of diabetes, particularly Type?2, across diverse age groups. Increasing awareness of early diagnosis and long-term disease management is driving higher demand for effective pharmacological therapies. Continuous innovation in drug development, including advanced insulin formulations and novel oral antidiabetic agents, is enhancing treatment outcomes and patient adherence. Supportive healthcare infrastructure and favorable reimbursement policies facilitate wider access to prescription medications. Leading pharmaceutical companies are actively expanding their portfolios and introducing new therapies to meet evolving patient needs. Additionally, the integration of digital health solutions and remote monitoring programs is contributing to improved disease management and market expansion.

Market Dynamics

Increasing Adoption of Advanced Drug Classes

The US diabetes care drugs market is witnessing significant growth through the adoption of advanced drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists. These therapies offer added benefits, including cardiovascular and renal protection, alongside effective glycemic control. Pharmaceutical companies are actively investing in research and development to introduce innovative treatment options with improved safety profiles. Regulatory support and streamlined approval processes are accelerating the introduction of novel therapies. Physicians are increasingly integrating these advanced drugs into standard treatment protocols for Type?2 diabetes and high-risk patients. Overall, this trend reflects a shift toward comprehensive, outcome-focused diabetes management.

Expansion of Distribution Channels and Digital Integration

Distribution channels for diabetes care drugs in the US are evolving, with retail and online pharmacies gaining prominence alongside traditional hospital-based channels. Online platforms are improving accessibility through home delivery services and digital prescription systems. Retail pharmacies continue to play a critical role by offering patient counseling and medication management services. Integration of digital health tools and remote monitoring programs supports treatment adherence and continuity of care. Enhanced supply chain efficiency ensures consistent availability of essential therapies. These developments are broadening market reach and strengthening overall growth in the diabetes care segment.

Market Segmentation

• Based on the diabetes type the market is segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and prediabetes.
• Based on the drug class the market is segmented into insulins, biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and others.
• Based on the formulation & route the market is segmented into oral tablets, subcutaneous injections, and inhalable.
• Based on the by distribution channel the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.

Type?2 Diabetes Segment Leading the US Market

The Type?2 diabetes sub?segment holds the largest share of the US diabetes care drugs market, reflecting its high prevalence among adult populations and strong ongoing clinical focus on long?term disease management. Rising incidence of lifestyle?related risk factors such as obesity and sedentary behaviour continues to expand the treated patient base, making Type?2 diabetes the dominant category in the region. Major pharmaceutical companies including Novo Nordisk, Eli Lilly, Sanofi, and AstraZeneca maintain extensive portfolios of therapies tailored for this cohort, reinforcing market leadership. Recent treatment guidelines prioritising early intervention and combination regimens support robust uptake. Additionally, payer coverage and public health initiatives in the US enhance access to advanced medications. This combination of demographic drivers and therapeutic innovation sustains growth momentum in the Type?2 diabetes segment.

SGLT2 Inhibitor Class as a Fastest?Growing Drug Category

Among drug classes, SGLT2 inhibitors are emerging as one of the fastest?growing segments in the US diabetes care drugs market, propelled by expanding clinical utility beyond glucose lowering to encompass cardiovascular and renal benefits. Products such as empagliflozin and dapagliflozin are gaining wider acceptance as evidence mounts for their role in reducing the progression of chronic kidney disease and heart failure, broadening their use beyond traditional diabetes care. Leading players like AstraZeneca, Boehringer Ingelheim, Merck & Co., and Johnson & Johnson are actively driving market expansion through portfolio enhancements and broader indication approvals. Updated clinical guidelines increasingly recommend these agents across diverse patient profiles, reinforcing prescriber confidence. Patient preference for therapies with multi?organ benefits and increasing insurance coverage further support uptake. Consequently, SGLT2 inhibitors are outpacing several legacy classes in growth trajectory within the US context.

Market Players Outlook

The major companies operating in the US diabetes care drugs market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co., Inc., and AstraZeneca PLC, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In October 2025, Biocon Biologics Ltd. announced expansion of its strategic collaboration with Civica, Inc. (Civica) to include a new Insulin Glargine medicine that will benefit patients in the US by increasing supply of affordable insulins. The multi-year transformational agreement between Biocon Biologics and Civica creates an exclusive distributorship arrangement where Biocon Biologics will manufacture and supply Insulin Glargine medicine to Civica, and Civica will commercialize under Biocon Biologics’ existing marketing approval.
• In February 2025, The FDA has approved Merilog (insulin-aspart-szjj), the first rapid-acting insulin biosimilar to Novolog, for improving glycemic control in adults and pediatric patients with diabetes. Available as a prefilled pen or multi-dose vial, Merilog offers a potentially more accessible option for managing mealtime blood sugar spikes.
• In June 2024, The FDA has approved AstraZeneca’s Farxiga (dapagliflozin) for improving glycaemic control in paediatric patients aged 10 years and older with type-2 diabetes, based on positive Phase III T2NOW trial results. Farxiga, a once-daily oral SGLT2 inhibitor, extends its established adult use to children, offering a clinically meaningful option for managing blood sugar in young patients.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the US diabetes care drugs Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.